[HTML][HTML] Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis
Neutropenia serves as a risk factor for severe infection and is a consequence of some
immune-depleting immunotherapies. This occurs in people with multiple sclerosis following …
immune-depleting immunotherapies. This occurs in people with multiple sclerosis following …
Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series
C Scavone, V Liguori, OJ Adungba… - Frontiers in …, 2024 - frontiersin.org
Disease modifying therapies (DMTs) used to treat multiple sclerosis (MS) can be associated
to the occurrence of hematological disorders. This systematic review aims to provide an …
to the occurrence of hematological disorders. This systematic review aims to provide an …
[HTML][HTML] Challenges in Diagnosis of COVID-19 Pneumonia under Ocrelizumab and De-Risking Strategies in Multiple Sclerosis—The Elephant Is (Still) in the Room
Severe SARS-CoV-2 infections may still be observed in people bearing risk factors, such as
the use of anti-CD20 monoclonal antibodies (mAbs), which are adopted in several …
the use of anti-CD20 monoclonal antibodies (mAbs), which are adopted in several …
Relapses and Serious Infections in Patients with Neuromyelitis Optica Spectrum Disorder Treated with Rituximab: A Swedish Single-Center Study
O Carlsson, DI Jonsson, L Brundin… - Journal of Clinical …, 2024 - mdpi.com
Neuromyelitis optica spectrum disorder (NMOSD) is a rare immune-mediated relapsing-
remitting disease of the central nervous system. The usage of rituximab, as relapse …
remitting disease of the central nervous system. The usage of rituximab, as relapse …
Ocrelizumab in people with primary progressive multiple sclerosis: A real-world multicentric study
Background Ocrelizumab is the only disease-modifying therapy (DMT) approved for the
treatment of people with primary progressive multiple sclerosis (pwPPMS). Objectives To …
treatment of people with primary progressive multiple sclerosis (pwPPMS). Objectives To …
[PDF][PDF] Multiple sclerosis and related disorders
D Baker, G Pryce, SJ Jackson, C Bolton… - Clinical neurology …, 1989 - academia.edu
abstract Cannabis-based medicines have recently been approved for the treatment of pain
and spasticity in multiple sclerosis (MS). This supports the original perceptions of people …
and spasticity in multiple sclerosis (MS). This supports the original perceptions of people …